

# Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

NCT06414889

---

Status	RECRUITING
Phase	Phase 1
Sponsor	M.D. Anderson Cancer Center
Enrollment	4 participants

## Key Eligibility Criteria

---

### Inclusion (13)

- Participants who meet all of the following criteria are eligible to be included in the study:
  - Are aged e 18 to 75 years
  - a. Once a favorable review of safety has been completed by the SMC in 3 participants aged e 18 years, the study will be opened to participants aged e 12 years.
  - Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative \[LAR\]), as described in Appendix 1, Section 13.1
  - Have a confirmed diagnosis of RUNX1 FPD, verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report.
- ... and 8 more (see full listing online)

### Exclusion (25)

- Participants who meet any of the following criteria are excluded from the study:
  - Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
  - Have uncontrolled bleeding
  - Are using supplemental oxygen
  - Have known severe splenomegaly (e 20 cm)
- ... and 20 more (see full listing online)

## Locations (1 total)

---

MD Anderson Cancer Center, Houston, Texas, United States